Systemic Inflammatory Response Syndrome. Systemic Inflammatory Response Syndrome of infectious origin without organ failure
Conditions
Interventions
Intervention 1: Intervention group: propolis intake with dose of 1000 mg/day for 10 days. Intervention 2: Intervention group: Intervention group: propolis intake with dose of 1000 mg/day plus melaton
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Age between 18-75 years Admission to the intensive care unit with the criteria of systemic inflammatory response syndrome (primary sepsis)
Exclusion criteria
Exclusion criteria: failure to start enteral nutrition during the first 48 hours of admission Patients with autoimmune disorders, cancer and advanced sepsis Sensitivity to bee products or known food allergies Patients with infection of the immunodeficiency virus, severe liver failure Severe and active bleeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical status. Timepoint: At the beginning of the study after 5 and 10 days of the intervention. Method of measurement: SOFA questionnaire.;White Blood Count. Timepoint: At the baseline and 10 days after intervention. Method of measurement: Sysmex K-1000 Hematology Analyzer.;Interleukin-6. Timepoint: At the baseline and 10 days after intervention. Method of measurement: Enzyme-linked immunosorbent assay.;Neutrophils. Timepoint: At the baseline and 10 days after intervention. Method of measurement: Sysmex K-1000 Hematology Analyzer and then the differential counts.;CRP. Timepoint: At the baseline and 10 days after intervention. Method of measurement: kit (Bionik, Iran) with the BT3500 (Biotecnica Instruments SpA -Italy) auto-analyzer.;Nutritional status. Timepoint: At the baseline and 10 days after intervention. Method of measurement: NUTRIC score questionnaire.;MDA. Timepoint: At the baseline and 10 days after intervention. Method of measurement: Fluorimetry.;Gavage intake record. Timepoint: Before and after intervention. Method of measurement: With measurement of amounts of gavage intake for each patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| PAB. Timepoint: At the baseline of the study and 10 days after intervention. Method of measurement: PAB assay.;APACHEII. Timepoint: At the baseline of the study and 10 days after intervention. Method of measurement: APACHEII questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNaseh Pahlavani
Mashhad University of Medical Sciences
Outcome results
None listed